Comirnaty Package Insert Reveals All…

Direct from the FDA Comirnaty package insert…

Obviously they are well aware of myocarditis, pericarditis, otherwise they wouldn’t have included it in the insert. They also admit that vaccine “may” not work. It is quite obvious that there have not been sufficient studies to rule out carcinogenicity, genotoxicity etc.

They admit that they have no idea what it does to fertility in males. They admit that female fertility has only been briefly and incompletely studied in rats (no long term).

5.2 Myocarditis and Pericarditis

Post marketing data demonstrate increased risks of myocarditis and pericarditis, particularly within 7 days following the second dose. The observed risk is higher among males under 40 years of age than among females and older males. The observed risk is highest in males 12 through 17 years of age. 

Although some cases required intensive care support, available data from short-term follow-up suggest that most individuals have had resolution of symptoms with conservative management. Information is not yet available about potential long term sequelae. The CDC has published considerations related to myocarditis and pericarditis after vaccination, including for vaccination of individuals with a history of myocarditis or pericarditis

5.5 Limitation of Effectiveness
COMIRNATY may not protect all vaccine recipients.

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility COMIRNATY has not been evaluated for the potential to cause carcinogenicity, genotoxicity, or impairment of male fertility. In a developmental toxicity study in rats with COMIRNATY there were no vaccine-related effects on female fertility [see Use in Specific Populations (8.1)].

And all this is for the one that has actually been “approved”. Of course there is much more in the insert that reveals the absolute lack of proper safety evaluation. But you can research the Pfizer EUA insert as well…

PDF: FDA.gov